{
  "ticker": "EMV",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02974121",
  "id": "02974121",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250730",
  "time": "0817",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250730/pdf/06m8z8c8zd7dt0.pdf",
  "summary": "### **EMVision Medical Devices Ltd \u2013 Appendix 4C Quarterly Report (30 June 2025) \u2013 Material Information Summary**  \n\n#### **Operational & Financial Highlights**  \n- **Pivotal FDA trial progress**: 5 of 6 sites activated for emu\u2122 bedside brain scanner. Target: 300 stroke patients enrolled (6\u201312-month timeline).  \n- **First Responder device**:  \n  - Successful aeromedical testing with Royal Flying Doctors Service.  \n  - Ethics approvals secured for pre-hospital studies (air/road).  \n- **Funding**:  \n  - **Cash balance**: **$10.5M** (30 June 2025).  \n  - **Non-dilutive grants**:  \n    - $5M Industry Growth Program grant awarded (June 2025).  \n    - $0.4M milestone payment received post-quarter.  \n    - Additional $4.4M in grants available.  \n  - **FY25 R&D tax rebate**: Expected Q4 2025 (prior year: $2.1M).  \n- **Cash burn**: Net operating outflow of **$2.06M** for the quarter.  \n- **Expansion**: Leased additional premises to establish pilot production line for First Responder.  \n\n#### **Upcoming Catalysts**  \n- **World Stroke Congress** (Oct 2025): Pivotal trial data presentation.  \n- **Military Health Symposium** (Aug 2025): First Responder demo for TBI applications.  \n\n**No material capital structure or liquidity changes identified.**",
  "usage": {
    "prompt_tokens": 7191,
    "completion_tokens": 321,
    "total_tokens": 7512,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T22:26:30.028239"
}